Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: Results of a multicentre open-label trial

Current Medical Research and Opinion

Volumn 22, Issue 10, 2006, Pages 1955-1964

  Watanabe, Luis A ^a   Wei, Meng ^b   Sun, Ningling ^c   Kim, Dongsoo ^d   Chiang, Chern En ^e   Ke, Yuannan ^f   Tseng, Chuen Den ^g   Coloma, Ricardo ^h   Vala, M ⁱ   Massaad, R ⁱ   Feig, P ⁱ   Guptha, Soneil ⁱ  

^a Perú   (Peru)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d Inje University College of Medicine   (South Korea)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h Clinica San Borja   (Peru)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Combination therapy; Hydrochlorothiazide; Hypertension; Losartan

Indexed keywords

CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID; VALSARTAN;

ADULT; AGED; ARTICLE; ASIAN; ASTHENIA; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG EFFECT; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; SIDE EFFECT; TABLET FORMULATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; VERTIGO;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES; VALINE;

EID: 33750515026     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X132514     Document Type: Article

References (40)

1. Lawes CM, Rodgers A, Bennett DA, et al.; for the Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21:707-16
2. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. New Engl J Med 2005;353:1124-34
3. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22:11-9
4. Yamamoto Y, Sonoyama K, Matsubara K, et al. The status of hypertension management in Japan in 2000. Hypertens Res 2002;25:717-25
5. Benedict CR. Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000;54:48-54
6. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6
7. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial [HOT Study Group]. Lancet 1998;351:1755-62
8. Soffer BA, Wright Jr JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-7
9. Ruilope LM, Simpson RL, Toh J, et al. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996;5:32-40
10. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996;156:278-85
11. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 2000;56:1879-85
12. Owens P, Kelly L, Nallen R, et al. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide - a randomized controlled trial. J Hypertens 2000;18:339-45
13. Rayner B, Trinder YA, Baines D, et al. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 2006;19:208-13
14. Critchley JAJH, Gilchrist N, Ikeda L, et al. A randomized, double-masked comparison of the antihypertensive efficacy and safety of combination therapy with losartan and hydrochlorothiazide versus captopril and hydrochlorothiazide in elderly and younger patients. Curr Ther Res Clin Exp 1996;57:392-407
15. Li Y, Liu G, Jiang B, et al. A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in Chinese patients with mild to moderate essential hypertension. Int J Clin Pract 2003;57:673-7
16. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418-26
17. Minami J, Ishimitsu T, Matsuoka H. Beneficial effects of combination therapy with losartan and low-dose hydrochlorothiazide in the treatment of essential hypertension [Japanese]. Nippon Jinzo Gakkai Shi 2005;47:864-9
18. Shiwaku K, Nogi A, Katajima K, et al. Prevalence of the metabolic syndrome using the modified ATP III definitions for workers in Japan, Korea and Mongolia. J Occup Health 2005;47:126-35
19. Benz JR, Black HR, Graff A, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9
20. Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 1999;13:275-81
21. Lasko BH, Laplante A, Hebert D, Bonnefis-Boyer S. Canadian valsartan study in patients with mild-to-moderate hypertension. Blood Press Monit 2001;6:91-9
22. Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005;27:1013-21
23. Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension [The Losartan Trial Investigators]. Clin Ther 2001;22:1186-203
24. Saito I, Kawabe H, Tsujioka M, et al. Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 guidelines [First Japanese Society of Hypertension]. Hypertens Res 2002;25:175-8
25. Chobanian AV, Bakris GL, Black HR, et al.; for the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003;289:2560-72
26. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
27. Saruta T. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Nippon Rinsho 2005;63:952-8
28. Dahlöf B, Devereux RB, Kjeldsen SE, et al.; for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
29. Dahlöf B, Sever PS, Poulter NR, et al.; for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906
30. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
31. Gradman AH, Brady WE, Gazdick LP, et al. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002;24:1049-61
32. Oparil S, Aurup P, Snavely D, et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 2001;87:721-6
33. Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004;6:614-20
34. Mimran A, Ribstein J, DuCailar G. Angiotensin II receptor antagonists and hypertension. Clin Exp Hypertens 1999;21:847-58
35. Byyny RL. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring [Ambulatory Blood Pressure Monitoring Study Group]. Blood Press Suppl 1996;2:71-7
36. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74
37. Koch-Weser J. Correlation of pathophysiology and pharmacology in primary hypertension. Am J Cardiol 1973;32:499-510
38. Black HR. The paradigm has shifted, to systolic blood pressure. Hypertension 1999;34:386-7
39. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000;85:251-5
40. Miura K, Soyama Y, Morikawa Y, et al. Comparison of four blood pressure indexes for the prediction of 10-year stroke risk in middle-aged and older Asians. Hypertension 2004;44:715-20